Referring to the bulletin from Mendus AB's annual general meeting, held on May 17, 2024, the company will carry out a reverse stock split in relations 1:20. The share will be traded under new ISIN code with effect from Jun 3, 2024. The order book will not change. Short name: IMMU Terms: Reverse split: 1:20 Current ISIN: SE0005003654 Last day of trading with current ISIN code: May 31, 2024 New ISIN code: SE0022239950 First day of trading with new ISIN code: Jun 3, 2024
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 21.02. | Mendus - CADENCE trial enrols first patient | Mendus has announced that the first patient has been enrolled in the CADENCE trial, sponsored by the Australasian Leukaemia and Lymphoma Group (ALLG). This is a multi-centre, randomised, controlled... ► Artikel lesen | |
| 21.02. | Mendus (OMX: IMMU) notes first patient enrolment in the CADENCE trial | Mendus has announced that the first patient has been enrolled in the Phase II AMLM22-CADENCE trial, sponsored by the Australasian Leukaemia and Lymphoma Group. The trial is a multicentre, randomised... ► Artikel lesen | |
| 20.02. | Mendus - Vididencel on track in AML going into 2025 | Mendus has reported its FY24 results, reflecting an active period. Lead programme, vididencel in acute myeloid leukaemia (AML), had encouraging data from the ADVANCE II trial in December, laying the... ► Artikel lesen | |
| 13.02. | Mendus - Focus firmly on pivotal-stage readiness in 2025 | Mendus's FY24 results and subsequent management presentation highlighted its focus on advancing lead asset, vididencel, to pivotal-stage readiness. Backed by robust long-term monotherapy data from ADVANCE... ► Artikel lesen | |
| 13.02. | Mendus AB: Mendus AB Year-end Report 2024 | Preparations for pivotal-stage readiness of vididencel in AML on trackThe hard work of the Mendus team to advance the company's lead product vididencel in acute myeloid leukemia (AML) continued to pay... ► Artikel lesen |
